Trials / Completed
CompletedNCT06354504
Bactericidal Permeability Protein Inhibitor and Interleukin-1beta Levels After Non-surgical Periodontal Treatment
Gingival Crevicular Fluid (GCF) Bactericidal/Permeability-increasing Protein (BPI) and Interleukin (IL)-1beta in Periodontitis Patients: Non-surgical Periodontal Treatment Effects
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Akdeniz University · Academic / Other
- Sex
- All
- Age
- 22 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study was to examine the relationship between healing response after non-surgical periodontal treatment and baseline gingival crevicular fluid (GCF) levels of bactericidal/permeability-increasing protein (BPI) and interleukin-1beta (IL-1ß).
Detailed description
Bactericidal/permeability-increasing proteins (BPI) specific and powerful effect against Gram negative bacteria and their LPSs is completely observable in biological fluids such as plasma, serum, and whole blood. Objective: It is the evaluation of periodontal disease effect of BPI and interleukin-1 beta (IL-1 β) levels in gingival fluid before and after non-surgical periodontal treatment (NSPT)in patients with periodontal disease. Method: Thirty systemically healthy and non-smoking individuals with periodontitis were included in the study. Before NSPT, the clinical parameters of plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAS), bleeding on probing (BOP) were measured. The gingival fluid samples were taken using the paper strip method. The same procedures were repeated at 6 weeks and 6 months after non-surgical periodontal treatment. ELISA method was used for the analysis of the samples
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Non-surgical periodontal treatment | Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure |
Timeline
- Start date
- 2019-11-19
- Primary completion
- 2020-09-20
- Completion
- 2020-09-20
- First posted
- 2024-04-09
- Last updated
- 2024-04-09
Locations
2 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06354504. Inclusion in this directory is not an endorsement.